|
AUPQ105799A0
(en)
|
1999-06-18 |
1999-07-08 |
Victor Chang Cardiac Research Institute, The |
Cell growth inhibition
|
|
AU2003218600C1
(en)
|
2002-03-26 |
2009-12-17 |
Zensun (Shanghai) Science & Technology Co., Ltd. |
ERBB3 based methods and compositions for treating neoplasms
|
|
US20040067532A1
(en)
|
2002-08-12 |
2004-04-08 |
Genetastix Corporation |
High throughput generation and affinity maturation of humanized antibody
|
|
US8505468B2
(en)
*
|
2002-11-19 |
2013-08-13 |
Sharp Kabushiki Kaisha |
Substrate accommodating tray
|
|
LT3173073T
(lt)
|
2004-05-03 |
2025-01-10 |
Ipsen Biopharm Ltd. |
Liposomos, skirtos vaistų pristatymui
|
|
KR101598229B1
(ko)
|
2007-02-16 |
2016-02-26 |
메리맥 파마슈티컬즈, 인크. |
Ｅｒｂｂ3에 대한 항체 및 이의 용도
|
|
CN101679974B
(zh)
|
2007-03-27 |
2015-09-30 |
航道生物技术有限责任公司 |
包含抗体替代轻链序列的构建体和文库
|
|
US8877688B2
(en)
|
2007-09-14 |
2014-11-04 |
Adimab, Llc |
Rationally designed, synthetic antibody libraries and uses therefor
|
|
EP3124497B1
(en)
|
2007-09-14 |
2020-04-15 |
Adimab, LLC |
Rationally designed, synthetic antibody libraries and uses therefor
|
|
US12529164B2
(en)
|
2007-09-14 |
2026-01-20 |
Adimab, Llc |
Rationally designed, synthetic antibody libraries and uses therefor
|
|
US9266967B2
(en)
|
2007-12-21 |
2016-02-23 |
Hoffmann-La Roche, Inc. |
Bivalent, bispecific antibodies
|
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
|
SG190572A1
(en)
|
2008-04-29 |
2013-06-28 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
|
TW201006485A
(en)
|
2008-06-03 |
2010-02-16 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
|
CA2726087A1
(en)
|
2008-06-03 |
2009-12-10 |
Tariq Ghayur |
Dual variable domain immunoglobulins and uses thereof
|
|
CN102149825B
(zh)
|
2008-07-08 |
2015-07-22 |
Abbvie公司 |
前列腺素e2双重可变结构域免疫球蛋白及其用途
|
|
WO2010019952A2
(en)
*
|
2008-08-15 |
2010-02-18 |
Merrimack Pharmaceuticals, Inc. |
Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted response
|
|
MY152068A
(en)
|
2009-03-20 |
2014-08-15 |
Genentech Inc |
Bispecific anti-her antibodies
|
|
CA2756244A1
(en)
|
2009-04-02 |
2010-10-07 |
Roche Glycart Ag |
Multispecific antibodies comprising full length antibodies and single chain fab fragments
|
|
MX2011010166A
(es)
*
|
2009-04-07 |
2011-10-11 |
Roche Glycart Ag |
Anticuerpos biespecificos anti-erbb-3/anti-c-met.
|
|
EP2417164A1
(en)
*
|
2009-04-07 |
2012-02-15 |
Roche Glycart AG |
Bispecific anti-erbb-2/anti-c-met antibodies
|
|
SG175077A1
(en)
*
|
2009-04-07 |
2011-11-28 |
Roche Glycart Ag |
Trivalent, bispecific antibodies
|
|
CA2761681A1
(en)
|
2009-05-13 |
2010-11-18 |
Sea Lane Biotechnologies, Llc |
Neutralizing molecules to influenza viruses
|
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
|
EA201200195A1
(ru)
*
|
2009-08-21 |
2012-12-28 |
Мерримаск Фармасьютикалс, Инк. |
АНТИТЕЛА ПРОТИВ ЭКТОДОМЕНА ErbB3 И ИХ ПРИМЕНЕНИЕ
|
|
WO2011028811A2
(en)
|
2009-09-01 |
2011-03-10 |
Abbott Laboratories |
Dual variable domain immunoglobulins and uses thereof
|
|
EP2478013B1
(en)
|
2009-09-16 |
2018-10-24 |
F.Hoffmann-La Roche Ag |
Coiled coil and/or tether containing protein complexes and uses thereof
|
|
AU2010303443A1
(en)
*
|
2009-10-09 |
2012-04-19 |
Merck Sharp & Dohme Corp. |
Generation, characterization and uses thereof of anti-Her 3 antibodies
|
|
AU2010306774A1
(en)
*
|
2009-10-14 |
2012-05-03 |
Merrimack Pharmaceuticals, Inc. |
Bispecific binding agents targeting IGF-1R and ErbB3 signalling and uses thereof
|
|
BR112012008833A2
(pt)
|
2009-10-15 |
2015-09-08 |
Abbott Lab |
imunoglobulinas de dominio variavel duplo e usos das mesmas
|
|
UY32979A
(es)
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
EP2496598B1
(en)
|
2009-11-04 |
2017-08-02 |
Affibody AB |
Her3 binding polypeptides
|
|
EP2896632B1
(en)
*
|
2009-11-13 |
2017-10-25 |
Daiichi Sankyo Europe GmbH |
Material and methods for treating or preventing HER-3 associated diseases
|
|
WO2011060380A1
(en)
*
|
2009-11-14 |
2011-05-19 |
The Regents Of The University Of California |
Pik3ca mutation status and sash1 expression predicts synergy between lapatinib and an akt inhibitor in her2 positive breast cancer
|
|
RS54795B1
(sr)
*
|
2009-12-22 |
2016-10-31 |
Roche Glycart Ag |
Anti-her3 antitela i njihova korišćenja
|
|
ES2602971T3
(es)
|
2010-03-02 |
2017-02-23 |
Kyowa Hakko Kirin Co., Ltd. |
Composición de anticuerpo modificado
|
|
KR101798679B1
(ko)
|
2010-03-11 |
2017-11-16 |
메리맥 파마슈티컬즈, 인크. |
３중 음성 및 기저형 유방암 치료 시의 ｅｒｂｂ３ 저해제의 용도
|
|
TW201138821A
(en)
|
2010-03-26 |
2011-11-16 |
Roche Glycart Ag |
Bispecific antibodies
|
|
MX343227B
(es)
*
|
2010-04-09 |
2016-10-28 |
Aveo Pharmaceuticals Inc |
Anticuerpos anti-erbb3.
|
|
US20120010388A1
(en)
*
|
2010-04-16 |
2012-01-12 |
Gottfried Himmler |
LeY SPECIFIC BIOTHERAPEUTIC
|
|
EP2566512A1
(en)
|
2010-05-04 |
2013-03-13 |
Merrimack Pharmaceuticals, Inc. |
Antibodies against epidermal growth factor receptor (egfr) and uses thereof
|
|
EP2571901B1
(en)
|
2010-05-20 |
2019-01-02 |
Ablynx N.V. |
Biological materials related to her3
|
|
AR082194A1
(es)
*
|
2010-07-06 |
2012-11-21 |
Aveo Pharmaceuticals Inc |
Anticuerpos anti-ron
|
|
PH12013500064A1
(en)
*
|
2010-07-09 |
2013-03-11 |
Exelixis Inc |
Combinations of kinase inhibitors for the treatment of cancer
|
|
EP3252072A3
(en)
|
2010-08-03 |
2018-03-14 |
AbbVie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
|
WO2012019024A2
(en)
*
|
2010-08-04 |
2012-02-09 |
Immunogen, Inc. |
Her3-binding molecules and immunoconjugates thereof
|
|
AU2011290672B2
(en)
|
2010-08-20 |
2015-07-09 |
Novartis Ag |
Antibodies for epidermal growth factor receptor 3 (HER3)
|
|
CN103068846B9
(zh)
|
2010-08-24 |
2016-09-28 |
弗·哈夫曼-拉罗切有限公司 |
包含二硫键稳定性Fv片段的双特异性抗体
|
|
JP2013539364A
(ja)
|
2010-08-26 |
2013-10-24 |
アッヴィ・インコーポレイテッド |
二重可変ドメイン免疫グロブリンおよびその使用
|
|
TW201302793A
(zh)
|
2010-09-03 |
2013-01-16 |
Glaxo Group Ltd |
新穎之抗原結合蛋白
|
|
CA2813796C
(en)
*
|
2010-10-18 |
2019-01-15 |
Mediapharma S.R.L. |
Erbb3 binding antibody
|
|
MX347981B
(es)
*
|
2010-11-01 |
2017-05-22 |
Symphogen As |
Composicion de anticuerpos pan-her.
|
|
US9155802B2
(en)
|
2010-11-01 |
2015-10-13 |
Symphogen A/S |
Pan-HER antibody composition
|
|
ITRM20100577A1
(it)
*
|
2010-11-02 |
2012-05-03 |
Takis Srl |
Immunoterapia contro il recettore erbb-3
|
|
AU2011338487B2
(en)
|
2010-12-06 |
2016-12-22 |
Merrimack Pharmaceuticals, Inc. |
Dosage and administration for preventing cardiotoxicity in treatment with ErbB2-targeted immunoliposomes comprising anthracyclin chemotherapeutic agents
|
|
SG191153A1
(en)
|
2010-12-23 |
2013-07-31 |
Hoffmann La Roche |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
|
SG191230A1
(en)
*
|
2010-12-23 |
2013-07-31 |
Nestec Sa |
Drug selection for malignant cancer therapy using antibody-based arrays
|
|
WO2012099968A1
(en)
*
|
2011-01-19 |
2012-07-26 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treating skin cancer associated diseases
|
|
WO2012103341A1
(en)
*
|
2011-01-27 |
2012-08-02 |
Merrimack Pharmaceuticals, Inc. |
Treatment of advanced solid stage tumors using anti-erbb3 antibodies
|
|
WO2012112730A2
(en)
|
2011-02-15 |
2012-08-23 |
Merrimack Pharmaceuticals, Inc. |
Compositions and methods for delivering nucleic acid to a cell
|
|
AR085404A1
(es)
|
2011-02-28 |
2013-09-25 |
Hoffmann La Roche |
Proteinas de union a antigeno
|
|
MX342034B
(es)
|
2011-02-28 |
2016-09-12 |
Hoffmann La Roche |
Proteinas monovalentes que se unen a antigenos.
|
|
US20140099264A1
(en)
|
2011-03-07 |
2014-04-10 |
F. Hoffman-La Roche Ag |
Means and methods for in vivo testing of therapeutic antibodies
|
|
US20140134170A1
(en)
*
|
2011-03-11 |
2014-05-15 |
Merrimack Pharmaceuticals, Inc. |
Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers
|
|
MX2013010444A
(es)
|
2011-03-15 |
2014-03-21 |
Merrimack Pharmaceuticals Inc |
Superar la resistencia a inhibidores de la via erbb.
|
|
US8476409B2
(en)
|
2011-04-19 |
2013-07-02 |
Merrimack Pharmaceuticals, Inc. |
Bispecific anti-IGF-1R and anti-ErbB3 antibodies
|
|
UA117218C2
(uk)
|
2011-05-05 |
2018-07-10 |
Мерк Патент Гмбх |
Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
|
|
CN103596592A
(zh)
*
|
2011-05-06 |
2014-02-19 |
梅里麦克制药股份有限公司 |
用于预防包含抗ErbB3试剂的联合治疗中的毒性药物间相互作用的方法
|
|
NO2707391T3
(https=)
*
|
2011-05-13 |
2018-04-07 |
|
|
|
WO2012158818A2
(en)
|
2011-05-16 |
2012-11-22 |
Fabion Pharmaceuticals, Inc. |
Multi-specific fab fusion proteins and methods of use
|
|
JP2014516960A
(ja)
*
|
2011-05-19 |
2014-07-17 |
インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） |
抗ヒトｈｅｒ３抗体及びその使用
|
|
AU2012271041A1
(en)
*
|
2011-06-16 |
2013-04-04 |
Merrimack Pharmaceuticals, Inc. |
Dosage and administration of anti-ErbB3 antibodies in combination with tyrosine kinase inhibitors
|
|
JPWO2012176779A1
(ja)
|
2011-06-20 |
2015-02-23 |
協和発酵キリン株式会社 |
抗ｅｒｂＢ３抗体
|
|
AU2012273361A1
(en)
*
|
2011-06-24 |
2013-03-21 |
Merrimack Pharmaceuticals, Inc. |
Dosage and administration of anti-ErbB3 antibodies in combination with paclitaxel
|
|
AU2012275850A1
(en)
*
|
2011-06-30 |
2013-03-21 |
Merrimack Pharmaceuticals, Inc. |
Dosage and administration of anti-ErbB3 antibodies in combination with paclitaxel for treatment of gynecological cancers
|
|
EP2736928B1
(en)
*
|
2011-07-28 |
2019-01-09 |
i2 Pharmaceuticals, Inc. |
Sur-binding proteins against erbb3
|
|
AU2012294326A1
(en)
*
|
2011-08-10 |
2013-03-21 |
Merrimack Pharmaceuticals, Inc. |
Treatment of advanced solid tumors using combination of anti-ErbB3 immunotherapy and selected chemotherapy
|
|
CA2843158A1
(en)
|
2011-08-26 |
2013-03-07 |
Merrimack Pharmaceuticals, Inc. |
Tandem fc bispecific antibodies
|
|
PH12014500483A1
(en)
*
|
2011-09-30 |
2014-04-14 |
Regeneron Pharma |
Anti-erbb3 antibodies and uses thereof
|
|
US9273143B2
(en)
|
2011-09-30 |
2016-03-01 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
|
|
JP6169085B2
(ja)
*
|
2011-10-06 |
2017-07-26 |
アベオ ファーマシューティカルズ， インコーポレイテッド |
抗ｅｒｂｂ３抗体に対する腫瘍応答の推定
|
|
AU2012335543C1
(en)
|
2011-11-09 |
2017-12-14 |
Beijing Cotimes Biotech Co., Ltd., |
HER3 antibodies and uses thereof
|
|
DK2797957T3
(da)
|
2011-11-23 |
2019-09-23 |
Medimmune Llc |
Bindingsmolekyler specifikke for her3 og anvendelser deraf
|
|
EP3590538A1
(en)
|
2011-12-05 |
2020-01-08 |
Novartis AG |
Antibodies for epidermal growth factor receptor 3 (her3)
|
|
US9975956B2
(en)
|
2011-12-22 |
2018-05-22 |
I2 Pharmaceuticals, Inc. |
Surrogate binding proteins which bind DR4 and/or DR5
|
|
TW201333035A
(zh)
|
2011-12-30 |
2013-08-16 |
Abbvie Inc |
針對ｉｌ－１３及／或ｉｌ－１７之雙特異性結合蛋白
|
|
JP6207399B2
(ja)
|
2012-01-13 |
2017-10-04 |
日本ケミファ株式会社 |
Ｐ２ｘ４受容体拮抗剤
|
|
CA2861124A1
(en)
|
2012-02-10 |
2013-08-15 |
Genentech, Inc. |
Single-chain antibodies and other heteromultimers
|
|
US20150037336A1
(en)
*
|
2012-02-22 |
2015-02-05 |
U3 Pharma Gmbh |
Combination of hb-egf binding protein and egfr inhibitor
|
|
WO2013138371A1
(en)
*
|
2012-03-12 |
2013-09-19 |
Merrimack Pharmaceuticals, Inc. |
Methods for treating pancreatic cancer using combination therapies comprising an anti-erbb3 antibody
|
|
US20130259867A1
(en)
|
2012-03-27 |
2013-10-03 |
Genentech, Inc. |
Diagnosis and treatments relating to her3 inhibitors
|
|
WO2013164689A2
(en)
|
2012-05-02 |
2013-11-07 |
Lantto, Johan |
Humanized pan-her antibody compositions
|
|
AU2013202947B2
(en)
|
2012-06-13 |
2016-06-02 |
Ipsen Biopharm Ltd. |
Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
|
|
US9717724B2
(en)
|
2012-06-13 |
2017-08-01 |
Ipsen Biopharm Ltd. |
Methods for treating pancreatic cancer using combination therapies
|
|
RU2639287C2
(ru)
|
2012-06-27 |
2017-12-20 |
Ф. Хоффманн-Ля Рош Аг |
Способ отбора и получения высокоселективных и мультиспецифичных нацеливающих групп с заданными свойствами, включающих по меньшей мере две различные связывающие группировки, и их применения
|
|
KR20150030744A
(ko)
|
2012-06-27 |
2015-03-20 |
에프. 호프만-라 로슈 아게 |
표적에 특이적으로 결합하는 하나 이상의 결합 단위를 포함하는 항체 Ｆｃ－영역 접합체의 제조 방법 및 그의 용도
|
|
AU2013322710A1
(en)
|
2012-09-25 |
2015-04-16 |
Glenmark Pharmaceuticals S.A. |
Purification of hetero-dimeric immunoglobulins
|
|
JP6440618B2
(ja)
|
2012-10-05 |
2018-12-19 |
アフィボディ・アーベー |
Ｈｅｒ３結合ポリペプチド
|
|
TW202037609A
(zh)
|
2012-11-01 |
2020-10-16 |
美商艾伯維有限公司 |
抗-vegf/dll4雙重可變區域免疫球蛋白及其用途
|
|
MA38165A1
(fr)
|
2012-11-08 |
2018-07-31 |
Hoffmann La Roche |
Protéines de liaison à l'antigène her3 se liant à l'épingle à cheveux beta de her3
|
|
AR093778A1
(es)
|
2012-11-08 |
2015-06-24 |
Hoffmann La Roche |
PROTEINAS LIGANTES DE ANTIGENO ANTI-HER3/HER4 DE UNION A LA HORQUILLA b DE HER3 Y A LA HORQUILLA b DE HER4
|
|
WO2014089127A1
(en)
|
2012-12-03 |
2014-06-12 |
Merrimack Pharmaceuticals, Inc. |
Combination therapy for treating her2-positive cancers
|
|
AR094403A1
(es)
|
2013-01-11 |
2015-07-29 |
Hoffmann La Roche |
Terapia de combinación de anticuerpos anti-her3
|
|
HK1220465A1
(zh)
|
2013-03-06 |
2017-05-05 |
Merrimack Pharmaceuticals, Inc. |
抗c-met串联fc双特异性抗体
|
|
MX2015010854A
(es)
|
2013-03-14 |
2016-07-20 |
Genentech Inc |
Combinaciones de un compuesto inhibidor de mek con un compuesto inhibidor de her3/egfr y metodos de uso.
|
|
WO2014144280A2
(en)
|
2013-03-15 |
2014-09-18 |
Abbvie Inc. |
DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-1β AND / OR IL-17
|
|
WO2014182970A1
(en)
*
|
2013-05-08 |
2014-11-13 |
Zymeworks Inc. |
Bispecific her2 and her3 antigen binding constructs
|
|
EP2821071A1
(en)
|
2013-07-04 |
2015-01-07 |
Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) |
Compounds for breast cancer treatment
|
|
US11305012B2
(en)
|
2013-09-24 |
2022-04-19 |
Medimmune, Llc |
Binding molecules specific for HER3 and uses thereof
|
|
BR112016006929A2
(pt)
|
2013-10-11 |
2017-09-19 |
Hoffmann La Roche |
Anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, métodos de preparação de anticorpo, de tratamento de pacientes e de geração de um anticorpo, composição farmacêutica e uso do anticorpo
|
|
US10519247B2
(en)
*
|
2013-11-01 |
2019-12-31 |
Board Of Regents,The University Of Texas System |
Targeting HER2 and HER3 with bispecific antibodies in cancerous cells
|
|
CN105849125B
(zh)
|
2013-11-07 |
2020-05-15 |
国家医疗保健研究所 |
神经调节蛋白变构抗her3抗体
|
|
EP3087394A2
(en)
|
2013-12-27 |
2016-11-02 |
Merrimack Pharmaceuticals, Inc. |
Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
|
|
KR102127408B1
(ko)
|
2014-01-29 |
2020-06-29 |
삼성전자주식회사 |
항 Her3 scFv 단편 및 이를 포함하는 항 c-Met/항 Her3 이중 특이 항체
|
|
JP6771385B2
(ja)
|
2014-02-28 |
2020-10-21 |
メルス ナムローゼ フェンノートシャップ |
二重特異性抗体および医薬組成物
|
|
WO2015130173A1
(en)
|
2014-02-28 |
2015-09-03 |
Merus B.V. |
Antibody that binds erbb-2 and erbb-3
|
|
AR099812A1
(es)
|
2014-03-21 |
2016-08-17 |
Abbvie Inc |
Anticuerpos y conjugados de anticuerpo y fármaco anti-egfr
|
|
SG11201608303QA
(en)
|
2014-04-04 |
2016-11-29 |
Del Mar Pharmaceuticals |
Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
|
|
KR102445502B1
(ko)
|
2014-04-10 |
2022-09-21 |
다이이찌 산쿄 가부시키가이샤 |
항her3 항체-약물 콘주게이트
|
|
WO2015157634A1
(en)
|
2014-04-11 |
2015-10-15 |
Kolltan Pharmaceuticals, Inc. |
Anti-erbb antibodies and methods of use thereof
|
|
FR3020063A1
(fr)
|
2014-04-16 |
2015-10-23 |
Gamamabs Pharma |
Anticorps humain anti-her4
|
|
MX2016014416A
(es)
*
|
2014-05-14 |
2017-02-23 |
Hoffmann La Roche |
Anticuerpos anti-her3 que se unen a la horquilla beta de her3.
|
|
WO2016022723A1
(en)
|
2014-08-05 |
2016-02-11 |
Merrimack Pharmaceuticals, Inc. |
Combination therapies for treating her2-positive cancers that are resistant to her2-targeted therapies
|
|
EP3227332B1
(en)
|
2014-12-03 |
2019-11-06 |
F.Hoffmann-La Roche Ag |
Multispecific antibodies
|
|
US10093733B2
(en)
|
2014-12-11 |
2018-10-09 |
Abbvie Inc. |
LRP-8 binding dual variable domain immunoglobulin proteins
|
|
JP2018513155A
(ja)
|
2015-04-17 |
2018-05-24 |
メリマック ファーマシューティカルズ インコーポレーティッド |
セリバンツマブを用いた併用療法
|
|
EP3091033A1
(en)
|
2015-05-06 |
2016-11-09 |
Gamamabs Pharma |
Anti-human-her3 antibodies and uses thereof
|
|
US11318131B2
(en)
|
2015-05-18 |
2022-05-03 |
Ipsen Biopharm Ltd. |
Nanoliposomal irinotecan for use in treating small cell lung cancer
|
|
AU2016271138A1
(en)
|
2015-05-29 |
2017-12-07 |
Merrimack Pharmaceuticals, Inc. |
Combination cancer therapies
|
|
US10184006B2
(en)
|
2015-06-04 |
2019-01-22 |
Merrimack Pharmaceuticals, Inc. |
Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
|
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
|
|
CN116059395A
(zh)
|
2015-06-29 |
2023-05-05 |
第一三共株式会社 |
用于选择性制造抗体-药物缀合物的方法
|
|
TW201716439A
(zh)
|
2015-07-20 |
2017-05-16 |
美國禮來大藥廠 |
Ｈｅｒ３抗體
|
|
JP7042739B2
(ja)
|
2015-08-20 |
2022-03-28 |
イプセン バイオファーム リミティド |
癌処置のためのリポソーム型イリノテカン及びｐａｒｐ阻害薬を使用する併用療法
|
|
TW202400181A
(zh)
|
2015-08-21 |
2024-01-01 |
英商益普生生物製藥有限公司 |
使用包含微脂伊立替康(irinotecan)及奧沙利鉑(oxaliplatin)之組合療法治療轉移性胰臟癌的方法
|
|
WO2017035482A1
(en)
*
|
2015-08-27 |
2017-03-02 |
Merrimack Pharmaceuticals, Inc |
Combination therapies for treatment of heregulin positive cancers
|
|
CA2999895A1
(en)
|
2015-09-24 |
2017-03-30 |
Expression Pathology, Inc. |
Quantifying met protein for cancer treatment
|
|
EP4647126A3
(en)
|
2015-10-16 |
2026-02-11 |
Ipsen Biopharm Ltd. |
Stabilizing camptothecin pharmaceutical compositions
|
|
SMT202100230T1
(it)
|
2015-10-23 |
2021-07-12 |
Fundacio Inst De Recerca Biomedica Irb Barcelona |
Molecole di legame che inibiscono la crescita tumorale
|
|
US20180271998A1
(en)
|
2015-12-04 |
2018-09-27 |
Merrimack Pharmaceuticals, Inc. |
Disulfide-stabilized fabs
|
|
KR101746152B1
(ko)
|
2015-12-07 |
2017-06-13 |
주식회사 이수앱지스 |
ＥｒｂＢ3에 특이적으로 결합하는 항체 및 그의 용도
|
|
CN106854244B
(zh)
*
|
2015-12-09 |
2020-05-22 |
南京英瀚斯生物科技有限公司 |
一种针对her3的纳米抗体及其临床应用
|
|
MA43416A
(fr)
|
2015-12-11 |
2018-10-17 |
Regeneron Pharma |
Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3
|
|
SG10201601719RA
(en)
|
2016-03-04 |
2017-10-30 |
Agency Science Tech & Res |
Anti-LAG-3 Antibodies
|
|
AU2017235450A1
(en)
|
2016-03-15 |
2018-08-16 |
Merrimack Pharmaceuticals, Inc. |
Methods for treating ER+, HER2-, HRG+ breast cancer using combination therapies comprising an anti-ErbB3 antibody
|
|
EP3430058A4
(en)
|
2016-03-15 |
2019-10-23 |
Generon (Shanghai) Corporation Ltd. |
MULTISPECIFIC FAB FUSION PROTEINS AND USES THEREOF
|
|
SG10201603721TA
(en)
|
2016-05-10 |
2017-12-28 |
Agency Science Tech & Res |
Anti-CTLA-4 Antibodies
|
|
BR112018075639A2
(pt)
|
2016-06-08 |
2019-04-09 |
Abbvie Inc. |
conjugados de anticorpo fármaco anti-egfr
|
|
JP2019524651A
(ja)
|
2016-06-08 |
2019-09-05 |
アッヴィ・インコーポレイテッド |
抗ｃｄ９８抗体及び抗体薬物コンジュゲート
|
|
WO2017214322A1
(en)
|
2016-06-08 |
2017-12-14 |
Abbvie Inc. |
Anti-b7-h3 antibodies and antibody drug conjugates
|
|
MX2018015285A
(es)
|
2016-06-08 |
2019-09-18 |
Abbvie Inc |
Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
|
|
AU2017277534A1
(en)
|
2016-06-08 |
2019-01-03 |
Abbvie Inc. |
Anti-EGFR antibody drug conjugates
|
|
AU2017279550A1
(en)
|
2016-06-08 |
2019-01-03 |
Abbvie Inc. |
Anti-B7-H3 antibodies and antibody drug conjugates
|
|
CN110402163A
(zh)
|
2016-11-02 |
2019-11-01 |
易普森生物制药有限公司 |
使用包括脂质体伊立替康、奥沙利铂、5-氟尿嘧啶(和甲酰四氢叶酸)的组合疗法治疗胃癌
|
|
US11273155B2
(en)
|
2016-12-12 |
2022-03-15 |
Daiichi Sankyo Company, Limited |
Combination of antibody-drug conjugate and immune checkpoint inhibitor
|
|
EP3554544A4
(en)
|
2016-12-16 |
2020-07-29 |
Bluefin Biomedicine, Inc. |
ANTI-PROTEIN 1 ANTIBODY CONTAINING AN ANTI-CUB DOMAIN (CDCP1), ANTIBODY-DRUG CONJUGATES AND THEIR METHODS OF USE
|
|
US20200157190A1
(en)
|
2016-12-19 |
2020-05-21 |
Abcam Plc |
Monovalent and divalent binding proteins
|
|
JP6679762B2
(ja)
|
2017-01-17 |
2020-04-15 |
第一三共株式会社 |
抗ｇｐｒ２０抗体及び抗ｇｐｒ２０抗体−薬物コンジュゲート
|
|
CN117982673A
(zh)
*
|
2017-02-28 |
2024-05-07 |
第一三共株式会社 |
抗her3抗体-药物偶联物的应用
|
|
MX2019011658A
(es)
|
2017-03-31 |
2019-11-18 |
Merus Nv |
Agente que se dirige al receptor 2 del factor de crecimiento epidermico humano (erbb-2) y anticuerpo biespecifico con sitios de union a antigeno que se unen a un epitopo sobre una parte extracelular de erbb-2 y el receptor 3 del factor de crecimiento epidermico humano (erbb-3), para el tratamiento de un individuo con un tumor positivo para erbb-2, erbb-2/erbb-3.
|
|
IL269656B2
(en)
|
2017-03-31 |
2024-06-01 |
Merus Nv |
Bispecific antibodies that bind ERBB-2 and ERBB3 for use in the treatment of cells with NRG1 fusion gene
|
|
EP3612567B1
(en)
|
2017-04-19 |
2024-09-11 |
Bluefin Biomedicine, Inc. |
Anti-vtcn1 antibodies and antibody drug conjugates
|
|
WO2018204153A1
(en)
*
|
2017-05-02 |
2018-11-08 |
Venomyx, Inc. |
Composition and methods for treating snake envenomation
|
|
TW202532104A
(zh)
|
2017-05-15 |
2025-08-16 |
日商第一三共股份有限公司 |
抗體－藥物結合物及其用途
|
|
JP7296891B2
(ja)
|
2017-05-17 |
2023-06-23 |
メルス ナムローゼ フェンノートシャップ |
乳癌のためのＥｒｂＢ－２／ＥｒｂＢ－３二重特異性抗体と内分泌療法との組み合わせ
|
|
CA3066918A1
(en)
|
2017-06-12 |
2018-12-20 |
Bluefin Biomedicine, Inc. |
Anti-il1rap antibodies and antibody drug conjugates
|
|
SG11202001050PA
(en)
|
2017-08-09 |
2020-03-30 |
Merus Nv |
Antibodies that bind egfr and cmet
|
|
AU2018320470B2
(en)
|
2017-08-23 |
2025-04-24 |
Daiichi Sankyo Company, Limited |
Antibody-drug conjugate preparation and lyophilization for same
|
|
IL324591A
(en)
|
2017-08-31 |
2026-01-01 |
Daiichi Sankyo Co Ltd |
Improved antibody-drug conjugate production methods
|
|
CA3074208C
(en)
|
2017-08-31 |
2023-10-03 |
Daiichi Sankyo Company, Limited |
Novel method for producing antibody-drug conjugate
|
|
WO2019118318A1
(en)
|
2017-12-12 |
2019-06-20 |
Calico Biolabs, Inc. |
Recombinant antibody comprising heavy chain genetically fused to signature peptide and uses thereof
|
|
WO2019185164A1
(en)
*
|
2018-03-29 |
2019-10-03 |
Hummingbird Bioscience Holdings Pte. Ltd. |
Her3 antigen-binding molecules
|
|
SG11202010496WA
(en)
|
2018-05-18 |
2020-12-30 |
Daiichi Sankyo Co Ltd |
Anti-muc1 antibody-drug conjugate
|
|
SG11202100653YA
(en)
|
2018-07-25 |
2021-02-25 |
Daiichi Sankyo Co Ltd |
Effective method for manufacturing antibody-drug conjugate
|
|
WO2020022475A1
(ja)
|
2018-07-27 |
2020-01-30 |
第一三共株式会社 |
抗体－薬物コンジュゲートの薬物部位を認識する蛋白質
|
|
CA3108044A1
(en)
|
2018-07-31 |
2020-02-06 |
Daiichi Sankyo Company, Limited |
Treatment of metastatic brain tumor by administration of antibody-drug conjugate
|
|
EA202190471A1
(ru)
|
2018-08-06 |
2021-05-24 |
Дайити Санкио Компани, Лимитед |
Комбинация конъюгата антитела-лекарственного средства и ингибитора тубулина
|
|
CN112739826A
(zh)
|
2018-08-23 |
2021-04-30 |
第一三共株式会社 |
抗体-药物缀合物的敏感性标志物
|
|
EP3847196A4
(en)
|
2018-09-07 |
2023-01-04 |
ITabMed (HK) Limited |
BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
|
|
WO2020059772A1
(ja)
|
2018-09-20 |
2020-03-26 |
第一三共株式会社 |
抗ｈｅｒ３抗体－薬物コンジュゲート投与によるｈｅｒ３変異がんの治療
|
|
KR102905497B1
(ko)
|
2018-12-11 |
2025-12-30 |
다이이찌 산쿄 가부시키가이샤 |
항체-약물 컨쥬게이트와 parp 저해제의 조합
|
|
US20220040324A1
(en)
|
2018-12-21 |
2022-02-10 |
Daiichi Sankyo Company, Limited |
Combination of antibody-drug conjugate and kinase inhibitor
|
|
WO2020132810A1
(en)
|
2018-12-24 |
2020-07-02 |
Generon (Shanghai) Corporation Ltd. |
Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
|
|
CN115843256B
(zh)
*
|
2020-10-15 |
2026-03-06 |
上海翰森生物医药科技有限公司 |
抗erbb3抗体或其抗原结合片段及其医药用途
|
|
AU2021378152A1
(en)
|
2020-11-11 |
2023-06-22 |
Daiichi Sankyo Company, Limited |
COMBINATION OF AN ANTIBODY-DRUG CONJUGATE WITH ANTI-SIRPα ANTIBODY
|
|
US12551584B1
(en)
|
2020-12-07 |
2026-02-17 |
Actinium Pharmaceuticals, Inc. |
Lewis Y radioimmunotherapy for the treatment of cancer
|
|
AR124681A1
(es)
|
2021-01-20 |
2023-04-26 |
Abbvie Inc |
Conjugados anticuerpo-fármaco anti-egfr
|
|
EP4304636A1
(en)
|
2021-03-11 |
2024-01-17 |
Elevation Oncology, Inc. |
Dosage and administration of anti-erbb3 (her3) monoclonal antibodies to treat tumors associated with neuregulin 1 (nrg1) gene fusions
|
|
AU2022293634A1
(en)
*
|
2021-06-15 |
2024-01-18 |
Beijing Sinotau Bio-Pharmaceuticals Technology Co., Ltd. |
Anti-her3 antibody, antibody drug conjugate containing the same, and use thereof
|
|
WO2023198138A1
(zh)
*
|
2022-04-13 |
2023-10-19 |
上海翰森生物医药科技有限公司 |
抗体或其抗原结合片段及其医药用途
|
|
EP4514391A1
(en)
|
2022-04-27 |
2025-03-05 |
Daiichi Sankyo Company, Limited |
Combination of antibody-drug conjugate with ezh1 and/or ezh2 inhibitor
|
|
CN119403829A
(zh)
|
2022-05-11 |
2025-02-07 |
第一三共株式会社 |
对于肿瘤抗原特异性的抗体和cd47抑制剂的组合
|
|
JP2025541340A
(ja)
|
2022-12-16 |
2025-12-18 |
フィアン セラピューティクス エルティーディー |
Ｃｕｂ ｄｏｍａｉｎ－ｃｏｎｔａｉｎｉｎｇ ｐｒｏｔｅｉｎ １（ｃｄｃｐ１）に対する抗体およびその使用
|
|
EP4721766A1
(en)
|
2023-06-02 |
2026-04-08 |
Daiichi Sankyo Company, Limited |
Combination of (anti-her3 antibody)-drug conjugate and rasg12c inhibitor
|
|
EP4737483A1
(en)
|
2023-06-30 |
2026-05-06 |
Daiichi Sankyo Company, Limited |
Antibody-drug conjugate production method including purification step using activated carbon material
|
|
WO2025188180A1
(en)
*
|
2024-03-04 |
2025-09-12 |
Merus N.V. |
Erbb-2 and erbb3 targeting agents for use in the treatment of malignant cells or cancers that have elevated nrg1 expression
|